

Resource Summary Report

Generated by [dkNET](#) on Sep 4, 2026

Ri-1

RRID:CVCL_1885

Type: Cell Line

Proper Citation

RRID:CVCL_1885

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1885

Proper Citation: RRID:CVCL_1885

Description: Cell line Ri-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Diffuse large B-cell lymphoma activated B-cell type

Defining Citation: [PMID:2985879](#), [PMID:3098690](#), [PMID:3159941](#), [PMID:3874327](#), [PMID:8558920](#), [PMID:9510473](#), [PMID:16960149](#), [PMID:22460905](#), [PMID:25355872](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:26727417](#), [PMID:28196595](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:31395879](#)

Comments: Miscellaneous: Originally assigned to be from a B-cell non-Hodgkin lymphoma, lymphocytic type., Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Ri-1

Synonyms: RI-1, RI1, RIVA, Riva

Cross References: CLO:CLO_0008814, EFO:EFO_0006477, CLDB:cl5090, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BioSample:SAMN03472482, BioSample:SAMN10988505,

cancercelllines:CVCL_1885, Cell_Model_Passport:SIDM01858, Cosmic:919144, Cosmic:1086342, Cosmic:1517635, Cosmic:2297018, Cosmic:2437312, DepMap:ACH-000398, DSMZ:ACC-585, DSMZCellDive:ACC-585, ECACC:96090512, EGA:EGAS00001000610, EGA:EGAS00001002554, GEO:GSM119557, GEO:GSM887539, GEO:GSM888622, GEO:GSM907521, GEO:GSM1035305, GEO:GSM1374849, IARC_TP53:28266, LiGeA:CCLE_317, PharmacDB:RI1_1314_2019, Progenetix:CVCL_1885, Wikidata:Q54950442

ID: CVCL_1885

Record Creation Time: 20220427T221459+0000

Record Last Update: 20260904T015525+0000

Ratings and Alerts

No rating or validation information has been found for Ri-1.

No alerts have been found for Ri-1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Enssle JC, et al. (2026) Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer cell, 44(7), 1437.

Manara P, et al. (2025) Blocking NRF2 Translation by Inhibition of Cap-Dependent Initiation Sensitizes Lymphoma Cells to Ferroptosis and CAR T-cell Immunotherapy. Cancer research.

Barisic D, et al. (2024) ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis. Cancer cell.

Phelan JD, et al. (2024) Response to Bruton's tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy. Cancer cell, 42(2), 238.

McCrury M, et al. (2024) Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma. Molecular cancer therapeutics, 23(3), 316.

Choi J, et al. (2024) Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. Cancer cell, 42(5), 833.

Eiken AP, et al. (2024) Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects. *Cancer research communications*, 4(5), 1328.

Zhuang X, et al. (2024) Functional genomics identifies N-acetylglucosamine extension of complex N-glycans as a mechanism to evade lysis by natural killer cells. *Cell reports*, 43(4), 114105.

Scuoppo C, et al. (2024) Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell Lymphoma. *Blood cancer discovery*, 5(6), 417.

Bolonsky A, et al. (2024) IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. *Cancer cell*, 42(7), 1185.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. *Cancer research communications*, 3(4), 576.

Venturutti L, et al. (2023) An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas. *Cancer discovery*, 13(1), 216.

Scheich S, et al. (2023) Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas. *Cancer discovery*, 13(8), 1862.

Kreer C, et al. (2023) Probabilities of developing HIV-1 bNAb sequence features in uninfected and chronically infected individuals. *Nature communications*, 14(1), 7137.

Portelinha A, et al. (2021) ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. *Cell reports. Medicine*, 2(7), 100350.